HER-2 expression was observed in 18/37 (48.6%) samples (Figure 2A,C), including 9/18 (50%) cutaneous melanomas, 8/16 (50%) oromucosal melanomas, and one-third (33.3%) of the digital melanomas. Here, ERBB2 is linked to cutaneous melanoma.